The MC4R agonist, setmelanotide, should be administered in patients with POMC, PCSK1, or LEPR deficiency and BBS, and the GLP-1 receptor agonists, semaglutide and liraglutide are also novel pharmacological agents that have been FDA approved for the treatment of childhood obesity. This evidence concerns the gene GLP1R and obesity due to leptin receptor gene deficiency.